[go: up one dir, main page]

BR0313154A - Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b - Google Patents

Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b

Info

Publication number
BR0313154A
BR0313154A BR0313154-8A BR0313154A BR0313154A BR 0313154 A BR0313154 A BR 0313154A BR 0313154 A BR0313154 A BR 0313154A BR 0313154 A BR0313154 A BR 0313154A
Authority
BR
Brazil
Prior art keywords
helper
lysine
cell
internal
cell epitopes
Prior art date
Application number
BR0313154-8A
Other languages
English (en)
Inventor
David Jackson
Weiguang Zeng
Original Assignee
Council The Queensland Inst Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council The Queensland Inst Of filed Critical Council The Queensland Inst Of
Publication of BR0313154A publication Critical patent/BR0313154A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"NOVOS LIPOPEPTìDEOS IMUNOGêNICOS QUE COMPREENDEM EPITOPOS DE CéLULA T-HELPER E DE CéLULA B". A presente invenção fornece moléculas sintéticas de lipopeptídeo imunogênico que compreendem epitopos de célula T-helper e de células B co-lineares, e métodos para sua produção e uso na geração de respostas imunes primárias e secundárias, e para a vacinação de animais contra antígenos particulares. Mais particularmente, a presente invenção fornece lipopeptídeos altamente solúveis onde a porção de lipídeo é ligada ao grupo de cadeia lateral terminal de uma lisina interna ou análogo de lisina, preferivelmente ao grupo de cadeia lateral terminal de um resíduo de diaminoácido interno. Preferivelmente a lisina interna ou análogo de lisina está posicionada entre o epitopo de T-helper e o epitopo de célula B ou no epitopo de T-helper.
BR0313154-8A 2002-08-12 2003-08-12 Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b BR0313154A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40283802P 2002-08-12 2002-08-12
PCT/AU2003/001018 WO2004014956A1 (en) 2002-08-12 2003-08-12 Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes

Publications (1)

Publication Number Publication Date
BR0313154A true BR0313154A (pt) 2005-08-02

Family

ID=31715903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313154-8A BR0313154A (pt) 2002-08-12 2003-08-12 Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b

Country Status (12)

Country Link
US (2) US7569225B2 (pt)
EP (2) EP2301972A1 (pt)
JP (2) JP4619120B2 (pt)
KR (1) KR101240547B1 (pt)
CN (3) CN1688606A (pt)
AT (1) ATE516308T1 (pt)
AU (1) AU2003250586B2 (pt)
BR (1) BR0313154A (pt)
CA (1) CA2494192C (pt)
DK (1) DK1543039T3 (pt)
ES (1) ES2369664T3 (pt)
WO (1) WO2004014956A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
JP2008510736A (ja) * 2004-08-26 2008-04-10 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド ウイルス感染の免疫療法
EP1791863A4 (en) * 2004-09-10 2008-11-19 Queensland Inst Med Res FORMULATIONS OF COPIED LHRH
EP1831259A2 (en) * 2004-12-21 2007-09-12 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
US20080233143A1 (en) * 2005-02-07 2008-09-25 Lipotek Pty Ltd. Adjuvanting Material
CA2597008A1 (en) 2005-02-08 2006-08-17 The Council Of The Queensland Institute Of Medical Research Immunogenic molecules
EP1874343A4 (en) 2005-04-19 2009-07-22 Lilly Co Eli MONOVALENT AND MULTIPURPOSE SYNTHETIC POLYSACCHARIDIC ANATIGENS FOR IMMUNOLOGICAL INTERVENTION IN PATHOLOGY
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US7943140B2 (en) * 2006-08-14 2011-05-17 Thymon, Llc Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
BRPI0604997A (pt) * 2006-11-30 2007-05-22 Fundacao Zerbini vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
US9289485B2 (en) 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
DK2200638T3 (en) * 2007-10-09 2016-06-06 Univ Melbourne Compositions for the transfection of cells
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
WO2010003178A1 (en) * 2008-07-07 2010-01-14 The University Of Melbourne A synthetic vaccine component
EP2356132A2 (en) 2008-10-16 2011-08-17 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
CA2916716C (en) * 2008-12-29 2018-06-26 Lonza Braine Sa Peptide intermediates used in the production of bivalirudin
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
US20130142827A1 (en) * 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
CA2809153C (en) * 2010-08-27 2023-09-26 Pantarhei Bioscience B.V. Use of hzp3 glycoprotein for treating prostate cancer
CN103189072B (zh) 2010-09-22 2018-02-09 因纳瓦克私人有限公司 免疫刺激方法
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US9328142B2 (en) * 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
WO2012168818A1 (en) 2011-06-08 2012-12-13 Ah Usa 42 Llc Infectious clones of torque teno virus
NZ702146A (en) * 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
US10420832B2 (en) * 2012-11-16 2019-09-24 United Biomedical, Inc. Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
WO2015157189A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP2018536645A (ja) * 2015-10-28 2018-12-13 味の素株式会社 免疫賦活剤
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
EP3432922B1 (en) 2016-03-21 2020-02-19 South Dakota Board of Regents Orf virus-based platform for vaccine delivery
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
CN107703294B (zh) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 一种用于检测鸡血清中cLHRH抗体效价的ELISA方法
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimised compounds
CN109991422A (zh) * 2017-12-29 2019-07-09 复旦大学 基于特异抗血清的棕榈酰化修饰蛋白质的检测方法
US20220054619A1 (en) * 2018-12-20 2022-02-24 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
CA3142501A1 (en) 2019-06-26 2020-12-30 Axelia Oncology Pty Ltd Novel molecules
AU2021271702A1 (en) 2020-05-13 2023-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RSV vaccine bearing one or more P gene mutations
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
TW202233647A (zh) * 2020-11-17 2022-09-01 挪威商霍夫賽思生物保健有限公司 呼吸治療
KR20230141851A (ko) * 2021-02-05 2023-10-10 암젠 인크 농축 하이브리도마 생성
CN113009141A (zh) * 2021-02-05 2021-06-22 深圳市国赛生物技术有限公司 化学发光免疫检测试剂盒、用途和检测方法
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
CN118267462A (zh) 2022-12-29 2024-07-02 硕腾服务有限责任公司 接种猪以抗伪狂犬病病毒的方法
WO2024149888A1 (en) * 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025128971A1 (en) 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5864008A (en) 1988-03-25 1999-01-26 James; Stephen Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6048538A (en) 1997-10-03 2000-04-11 United Biomedical, Inc. Peptides derived from the non-structural proteins of foot and mouth disease virus as diagnostic reagents
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
JP4699612B2 (ja) 1999-02-05 2011-06-15 ザ ユニバーシティ オブ メルボーン Ｔヘルパー細胞エピトープ
CA2404327A1 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants

Also Published As

Publication number Publication date
ATE516308T1 (de) 2011-07-15
CN1688606B (zh) 2013-12-25
KR20050053608A (ko) 2005-06-08
CN101121754B (zh) 2012-02-29
JP4619120B2 (ja) 2011-01-26
US20100092500A1 (en) 2010-04-15
JP2010155832A (ja) 2010-07-15
US20070066534A1 (en) 2007-03-22
EP2301972A1 (en) 2011-03-30
DK1543039T3 (da) 2011-10-31
CN1688606A (zh) 2005-10-26
ES2369664T3 (es) 2011-12-02
CA2494192A1 (en) 2004-02-19
KR101240547B1 (ko) 2013-03-08
JP5265511B2 (ja) 2013-08-14
AU2003250586A1 (en) 2004-02-25
AU2003250586B2 (en) 2010-09-23
JP2006513140A (ja) 2006-04-20
HK1113163A1 (en) 2008-09-26
US7569225B2 (en) 2009-08-04
CN101121754A (zh) 2008-02-13
CA2494192C (en) 2013-01-22
EP1543039A1 (en) 2005-06-22
EP1543039A4 (en) 2007-09-19
US8367067B2 (en) 2013-02-05
WO2004014956A1 (en) 2004-02-19
EP1543039B1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
BR0313154A (pt) Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b
BR0313101A (pt) Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
RU2434638C2 (ru) Вакцина альфа токсоида с.perfringens
BR9912177A (pt) Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
AU3847801A (en) Proteosome influenza vaccine
BR9810614A (pt) Composições de vacinas de óleo-em-água
MA30298B1 (fr) Composition
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
NZ562998A (en) Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
BR0213358A (pt) Uso de flibanserina
PT714444E (pt) Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
JP2020536946A (ja) トリテルペンサポニン類似物
BR9912176A (pt) Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
WO2003099830A3 (en) Cardiolipin compositions, methods of preparation and use
BRPI0407181A (pt) Formulação farmacêutica
EA201201221A1 (ru) Фармацевтическая композиция для контрацепции и заместительной гормональной терапии
DK1259259T3 (da) Mucosal adjuvansformulering
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
AR035750A1 (es) Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
GB9612214D0 (en) Vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.